t(12;21)(p13; q22) ETV6-RUNX1(TEL-AML1) Fusion detection Qualitative One step RT-PCR Kit

برای قیمت تماس بگیرید

This translocation is not detectable by conventional cytogenetics and constitutes the most frequent rearrangement in childhood ALL. It occurs in approximately 25% of childhood ALL. Most positive patients are between 1 and 12 years old at the time of diagnosis and the peak is between 2 and 5 years old. in all cases, particularly ALL and pre-B-ALL, and rarely in pro-B-ALL precursor-B cell immunophenotype is observed.
In addition, these patients are characterized by WBC deficiency at diagnosis(<50000/l). Interestingly, the vast majority of patients have a non-hyper diploidy DNA content (DNA index = 1), most of them have myeloid markers and the majority (70–80%) show deletion of the non- rearranged TEL allele. So far, t(12;21) has not been found in T-ALL or AML. It has never been described in infant leukemias (age less than 1 year) and the frequency in adult leukemic patients is low (<2%).
Several studies reported favorable outcomes for t(12;21) positive patients, in both retrospective studies and prospective studies with relatively short follow-up. This investigational use kit (IUO) has been manufactured for qualitative detection of ETV6-RUNX1 fusion transcripts in ALL cases.

SKU: APETVK1 Category:

Description

Advantages and applications:

  • Qualitative detection of translocation or fused genes in leukemia
  • One-step test without the need for separate cDNA synthesis
  • Accelerate test response
  • High sensitivity and specificity
  • Using the best reagents
  • Has positive and negative control
  • Reducing the risk of contamination
  • With reporting instructions
  • It has Job Aid for ease of use by the operator
  • Competitive in terms of quality and price with top brands
  • Licensed by the General Department of Medical Equipment and Supplies (IUO)
Menu
error: Content is protected !!